Towards Healthcare

News

Your Daily Gateway to Essential News in Healthcare, Science, Technology and Business Worldwide

 Supreme Court to Weigh Whether Federal Law Blocks Roundup Cancer Lawsuits
23 January 2026

Supreme Court to Weigh Whether Federal Law Blocks Roundup Cancer Lawsuits

The U.S. Supreme Court said it will take up a closely watched case that could determine whether tens of thousands of people who claim the weedkiller Roundup caused their cancer will be allowed to pursue their lawsuits in court, or whether federal pesticide law will effectively shut those cases down....

Bayer Sues Pfizer, Moderna, BioNTech and J&J Over Alleged COVID-19 Vaccine Patent Infringement
23 January 2026

Bayer Sues Pfizer, Moderna, BioNTech and J&J Over Alleged COVID-19 Vaccine Patent Infringement

Bayer has launched a new round of high-stakes patent litigation against the makers of several leading COVID-19 vaccines, alleging that they improperly used intellectual property originally developed by Monsanto decades ago.  In separate lawsuits filed in U.S. federal courts, the German life sc...

Tanabe’s positive results bring life to EPP and XLP patients
23 January 2026

Tanabe’s positive results bring life to EPP and XLP patients

Introduction Tanabe Pharma America, Inc., formerly Mitsubishi Tanabe Pharma America, is a U.S. division of Japan’s Tanabe Pharma Corporation. The company is known for its marketing skills and introducing treatments for extreme areas of rare diseases, immune-inflammation and CNS. The company&r...

AstraZeneca speed up its revenue game to meet stability by 2030
23 January 2026

AstraZeneca speed up its revenue game to meet stability by 2030

Introduction AstraZeneca is a science-driven biopharmaceutical company that believes in establishing, marketing and exploring prescription drugs in respiratory, rare diseases, metabolism, oncology, renal, and cardiovascular areas. The company’s science-based vision is aligned with its investm...

Pfizer’s unpredictable move just after the ‘no deal’ with BioNTech assumption
23 January 2026

Pfizer’s unpredictable move just after the ‘no deal’ with BioNTech assumption

Introduction Pfizer is a biotechnology corporation and a leading multinational pharmaceutical company, building its recognition since 1849, and is known for its vaccines and medicines and their effectiveness. The company is ruling in the areas of rare disease, internal medicine, immunology and onco...

Biohaven into the battlefield with Lilly
23 January 2026

Biohaven into the battlefield with Lilly

Introduction Biohaven Biopharmaceutical Company is recognised for its expertise in developing, marketing, and exploring innovative treatments for conditions such as immunology, oncology, and neuropsychiatric disorders. The company aims to expand and accelerate its exclusive platforms for protein de...

Functional Gut Clinic's new branch to digest all odds in the research space
22 January 2026

Functional Gut Clinic's new branch to digest all odds in the research space

Introduction Functional Gut Clinic (FGC), the expert face of modern gastrointestinal diagnostics, which also provides effective tests for conditions like leaky gut, reflux and IBS with the help of technology such as manometry, breath test, etc., is highly promoting its personalised clinical care. T...

Entheon and Nutravisor’s partnership to fuel the healthcare business
22 January 2026

Entheon and Nutravisor’s partnership to fuel the healthcare business

Introduction Entheon Biomedical Corp., a Canada-based biotech R&D entity, is focused on establishing psychedelic-related therapies with the help of DMT and commercialising its treatments to known physicians and clinics. The main business area of this company is psychedelic therapeutics, and the...

Novo celebrates Wegovy’s reach in this month of launch
22 January 2026

Novo celebrates Wegovy’s reach in this month of launch

Introduction A Danish-based multinational pharmaceutical company, Novo Nordisk, has been fighting serious chronic conditions since 1923 via innovative drugs to promote a long-term healthy lifestyle. Its main commercial areas are obesity and diabetes. Alongside the company’s new delivery syste...

Gosebruch promises to sail the ship with its oars of hardship
22 January 2026

Gosebruch promises to sail the ship with its oars of hardship

Introduction Henry Gosebruch, a G100 Next Gen graduate a valuable member of the board of directors at Acelyrin, known for its commendable work at AbbVie as a Former Executive Vice President and Chief Strategy Officer. The acquisitions, partnership management, and other business development speciali...